

# CV

**Eva Tiensuu Janson, Professor of Medicine, M.D., Ph.D.**

---

Born January 19, 1963

Married to Jan Dumanski, Professor of Experimental Pathology, Uppsala University

Two children; Carolina born 1991 and Sofia born 1994

## Professional preparations

- Specialist of Internal Medicine 2002
- Specialist of Endocrinology and Diabetology 2001
- Associate Professor Experimental Medicine, Uppsala University 1999
- Doctor Medical Sciences (Ph.D.), Department of Internal Medicine, Uppsala University, 1995-05-17, Thesis: Carcinoid tumors – Clinical aspects and the use of somatostatin analogues for diagnosis and treatment
- License to practice medicine 1994
- University Medical Degree, Uppsala University 1988

## Appointments

- Deputy vice-rector Disciplinary Domain of Medicine and Pharmacy, Uppsala University 2020-07-01 – ongoing
- Dean, Faculty of Medicine, Uppsala University 2014-07-01 – 2020-06-30
- Department Head, Dept. of Medical Sciences, Uppsala University 2009-07-01 – 2014-06-30
- Professor of Medicine at the Dept. of Medical Sciences, Uppsala University, 2008 – ongoing.
- Senior lecturer at the Dept. of Medical Sciences, Uppsala University 2004 – 2008.
- Senior consultant at the Dept. of Endocrine Oncology, Uppsala University Hospital 2002 - ongoing
- Residency in Internal Medicine and Endocrinology, Uppsala University Hospital, 1994-04-01 – 2001-12-31, interrupted 1997-09-01 – 2000-01-01.
- Junior researcher funded by the Medical Research Council and the Medical Faculty of Uppsala University 1997-09-01 - 1999-12-31.
- Internship including one year of research, Uppsala University Hospital, 1991-01-01 – 1994-03-31.
- Work as a junior doctor combined with research time, Uppsala University Hospital, 1988-08-31 – 1990-12-31.
- Maternal leave 91-02-20 – 92-09-01 and 94-08-08 – 95-09-15.

### **Leadership experience in science; International**

- Chair European Neuroendocrine Tumour Society (ENETS) 2022 –ongoing
- Chair Nordic Neuroendocrine Tumor Group 2004 – ongoing
- Chair ENETS Center of Excellence program 2018 - 2022
- Vice-president European Society for Clinical Investigations 2010 - 2011

### **Leadership experience in science; National**

- Chair Steering committee Biobank Sweden January 2022 - ongoing
- Chair Uppsala node, ULF-project August 2020 - ongoing
- Integration director SciLifeLab, Uppsala 2020 - ongoing
- Chair EIT-Health Board, Uppsala University 2014 ongoing
- Chair of ALF-funding priority committee, cancer, Stockholm 2011 - 2013.

### **Leadership experience in science; Local**

- Chair Universitetsjukvårdsnämnd Uppsala University Hospital 2021
- Chair local SFO steering groups 2014 - 2017
- Chair Uppsala Antibiotic Center 2016 -
- Chair of various working groups at Uppsala University and University Hospital during the past 15 years

### **Membership in Academic Societies**

- Member of the Swedish Society of Medicine
- Member of the Swedish Endocrine Society
- Member of the Swedish Research Councils Network Group for Endocrine Abdominal Tumors
- Member of the Nordic Neuroendocrine Tumor Group (at present chair)
- Member of the European Neuroendocrine Tumor Society (at present chair)
- Member of European Society of Medical Oncology (Faculty Member neuroendocrine tumors)

### **Member National Committees**

- Biobank Sweden
- Genomic Medicine Sweden
- The Swedish Government's collaboration group for Health and Life Science

### **Leadership experience education; National**

- Chair program committee Medical Program 2011 - 2014
- Course director for Compulsory Graduate Courses b1998 - 2001
- Course director, undergraduate course of Internal Medicine, Uppsala University with 150 students per year 2002 - 2008
- Vice chairman of Stadium I (1<sup>st</sup> semester) of the Reformed Medical Program at Uppsala University 2002 - 2004
- Chairman of Stadium II (5<sup>th</sup>-8<sup>th</sup> semesters) of the Reformed Medical Program at Uppsala University 2005 - 2011

### **Clinically oriented assignments; National**

- Uppsala University representative in the steering group for Comprehensive Cancer Center application 2021 - ongoing
- Uppsala University representative in the Akademiska Hospital steering group for Highly specialized care 2020 - ongoing
- Chair standardized caring plan GEP-NET 2017 - ongoing
- Chair Steering committee National Quality Registry for GEP-NET 2016 - ongoing
- Uppsala University Hospital representative in the ERN initiative EURACAN 2016 - ongoing
- Chair for the National Caring program for GEP-NET 2015 - ongoing

### **Invited Speaker/Organizer of Scientific Meetings**

Participated as invited speaker or chair at scientific conferences 2-3 times per year during the last 15 years.

Organizing scientific meetings on a national and international level 2-3 times per year during the last 15 years.

### **Supervisor Ph.D. students, graduated**

Staffan Welin	Graduated 2007. "Midgut Carcinoid Tumours – New Diagnostic Procedures and Treatment".
Janet Cunningham	Graduated 2007. "Tumour Biological Factors Characterizing Metastasizing Serotonin-producing Ileocaecal Carcinoids".
Apostolos Tsolakis	Graduated 2008. "Characterization of Endocrine Cells and Tumours in the stomach".
Malin Grönberg	Graduated 2010. "Expression of Neuroendocrine Markers in Normal and Neoplastic Tissue with an emphasis on Ghrelin and Obestatin".
Abir Ali	Graduated 2019. Gastroenteropancreatic Neuroendocrine Neoplasms Grade 3: Biological and Clinical Aspects".

### **Co-supervisor Ph.D. students, graduated**

Marie-Louise Fjällskog	Graduated 2002. "Current Medical Treatment of Endocrine Pancreatic Tumors and Future Aspects".
Eva Ludvigsen	Graduated 2006. "Somatostatin Receptor Expression and Biological Function in Endocrine Pancreatic Cells".
Anthoula Koliadi	Graduated 2014. "The Prognostic Impact of Proliferation Markers in Breast Cancer with Emphasis on Cyclin B1 and PPH3".
Kleopatra Georgantzi	Graduated 2018. "On the Diagnostics of Neuroblastoma: Clinical and Experimental Studies".

### **Supervisor Ph.D. students, ongoing**

Ieva Lase	Supervisor, halftime control 2021
Dimitrios Papantoniou	Supervisor, halftime control planned for June 2022
Maria Wedin	Co-supervisor

### **Membership in research councils and committees and other funding committees**

- Scientific secretary, the Research Ethics Committee at Uppsala University 2001 - 2003.
- Substitute in the Medical and Pharmaceutical faculty's graduate studies group between 2001– 2002.
- Substitute in the working group for research ethics in medicine, the Swedish Research Council, 2002 - 2003.
- Substitute at the Central Ethical Review Board, 2004 - 2009.
- Full member of the Research and Development foundation at the National Board for Forensic Medicine, 2005-2006.
- Member of the bioethics group for the Swedish LifeGene project, 2006 - 2007.
- Member of the European Society for Clinical Investigations (ESCI) Council with special responsibility for the contacts with the associated journal, 2007 - 2010.
- Member of ALF-funding priority committee, cancer, Stockholm, 2008-2010
- Member of priority committee for the Cancer foundation, Uppsala University Hospital
- Member of the funding committee at the Swedish Medical Society 2010-2012.
- Member of the evaluation committee for Clinical Academic Groups (CAG), NTNU, Trondheim October 2019, 2020, 2021

### **Evaluator for Academic Positions**

- Senior lecturer internal medicine, Karolinska Institute 2009
- Promotion to professor of gastroenterology, Lund University 2009
- Senior lecturer in clinical science, Linköping University 2017
- Professor of Endocrinology, Lund University 2021
- Professor of Oncology, Tartu University, 2021

### **Other Faculty Assignments**

- Substitute of the Board of the Dept of Medical Sciences, Uppsala University, 2002-2005.
- Full member of the Board of the Dept of Medical Sciences, Uppsala University, 2005- 2008.

### **Editorial Board Assignments**

Member of the editorial board of European Journal of Clinical investigations 2009 – 2021.

### **Faculty Opponent for Ph.D. dissertation**

**Tobias Hofving** 2019, Faculty of Medicine, Sahlgrenska Academy, Gothenburg University, Sweden

**Kristina BV. Dossing** "microRNAs in Neuroendocrine Neoplasms – From cell function to patient treatment". 2018, Faculty of Health Sciences, University of Copenhagen, Denmark.

**Camilla B. Johnbeck** "Positron Emission Tomography for Neuroendocrine Tumors". 2016, Faculty of Health Sciences, University of Copenhagen, Denmark.

**Andreas Pfeifer** "Theranostics in Neuroendocrine Tumors: Evaluation of a New PET Tracer & Peptide Receptor Radionuclide Therapy Response". 2015, Faculty of Health Sciences, University of Copenhagen, Denmark.

**David Velázquez-Fernández** "Insights into the Transcriptomic Profiling of Adrenocortical Tumors". 2013 Karolinska Institutet, Stockholm, Sweden.

**Tina Binderup** "Quantitative gene expression in relation to functional imaging of neuroendocrine tumors with PET and SPECT: Translational Molecular Imaging Studies". 2010, Faculty of Health Sciences, University of Copenhagen, Denmark.

**Sveinung Sörhaug** "The Pulmonary Neuroendocrine system", 2007, Norwegian University for Science and Technology, Trondheim, Norway.

### **Member of Examination Board**

Member of examination boards for Ph.D. and licentiate thesis >20 times

### **Regular assignment as reviewer for scientific journals**

Gastroenterology, Neuroendocrinology, Endocrine Related Cancer, Scandinavian Journal of Gastroenterology, Regulatory Peptides, Journal of Controlled Release, European Journal of Endocrinology, Acta Oncologica, European Journal of Clinical Investigations

### **Production of educational material**

#### *Chapters in textbooks*

Janson ET and Öberg K. The carcinoid syndrome. In Gastroenterology and Hepatology: the Modern Clinician's Guide. (Elsevier Science) Eds Weinstein WM, Hawkey CJ and Bosch J, 2005; chapter 110: pp 823-830.

Janson ET and Öberg K. Carcinoid Tumors. In Oncology-Hematology Source Book: Evidence-Based Practice. (McGraw Hill) Eds. Boyiadzis, Lebowitz Fojo.

Ljunggren Ö and Tiensuu Janson E. Endokrina sjukdomar. In Medicin Eds Lindgren S, Engström-Laurent a, Karason K, Janson ET. 2012 and 2017, kapitel 10, pp593-638.

Tiensuu Janson E. Neuroendokrina buk tumörer. In Gastroenterologi och Hepatologi, Liber.

#### *Editor*

Medicin. Studentlitteratur. Editors Lindgren S, Engström-Laurent a, Karason K, Janson ET.

## Clinical Qualifications

### Clinical competence and training

- University Medical Degree, Uppsala University 1988-06-10.
- License to practice medicine 1994-04-05-
- Specialist of Endocrinology and Diabetology 2001-04-24.
- Specialist of Internal Medicine 2002-01-10.
- Senior Consultant, Endocrine oncology unit, Uppsala University Hospital

## Management Qualifications

### Formal training

- UGL – development of groups and leaders 1 week, November 1999.
- Leadership training for female leaders 1 week, 2003. Course leader Barbro Dahlbom-Hall.
- Leadership program for young clinicians – Communication, leadership and development, 2001 - 2003 (35 days)
- Kommunikation och ledarskap 2008 (3 days)
- Basprogram för Chefer, Uppsala Universitet 2009 -2 010 (12 days)
- Leadership program for women at Uppsala University 2013 (10 days)
- HeLP10, Sveriges Universitets- och högskoleförbunds högre ledarprogram 2018 - 2019 (27 days)

### Other management and social leadership ability

Outside the university work I was leading the work of starting a child care unit for graduate students' children and was elected as chairman for this unit. The work included finding a place for the unit and equipping the premises. It also involved hiring staff and having the full responsibility for the staff and economy of the child care unit. This assignment continued for 2 years.

I was also elected as chairman for another child care unit (for children to staff at the university hospital) with the same kind of responsibilities and continued with this assignment for 4 years.

## List of Publications (H-index 43 web of science)

### Thesis

**Janson ET.** Carcinoid tumors - clinical aspects and the use of somatostatin analogues for characterization and treatment. (1995) Acta Univ. Ups. Comprehensive summaries of Uppsala dissertations from the faculty of medicine 551. ISBN 91-554-3537-8.

### Scientific publications

1. Grandér D, Öberg K, Lundqvist M-L, **Janson ET**, Eriksson B, Einhorn S. Interferon-induced. Enhancement of 2'5'-Oligoadenylate Synthetase in Mid-gut Carcinoid Tumours. Lancet 1990; 336: 337-40.

2. **Janson ET**, Ahlström H, Andersson T, Öberg K. Octreotide and interferon alfa, a new combination for the treatment of malignant carcinoid tumours. *Eur J Cancer*, 1992, Vol 28A, No 10:1647-1650.
3. Rönblom LE, **Janson ET**, Perers A, Öberg KE, Alm GV. Characterization of anti-interferon-alpha-antibodies appearing during recombinant interferon-alpha2a treatment. *Clin. exp. Immunol*, 1992; 89: 330-335.
4. **Janson ET**, Rönblom L, Ahlström H, Grandér D, Alm G, Einhorn S, Öberg K. Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumours: a randomized trial. *Annals of Oncology*, 1992; 3: 635-638.
5. Westlin JE, **Janson ET**, Ahlström H, Nilsson S, Åkerström G, Öberg K. Scintigraphy using an 111-Indium labelled somatostatin analogue for localization of neuroendocrine tumors. *Antibody, Immunoconjugates and Radiopharmaceuticals*, 1992; Vol 5: No 4: 367-384.
6. **Janson ET**, Kauppinen HL, Öberg K. Combined alpha and gamma interferon therapy for malignant carcinoid tumors: a phase II trial. *Acta Oncologica*; 1993; Vol 32: No 2: 231-233.
7. **Janson ET** and Öberg K. Long-term management of the carcinoid syndrome - treatment with octreotide alone and in combination with alpha-interferon. *Acta Oncologica*, 1993; Vol 32: No 2: 225-229.
8. **Janson ET**, Westlin JE, Ahlström H, Eriksson B, Nilsson S, Åkerström G, Öberg K. Somatostatin receptor scintigraphy - recent advances imaging endocrine pancreatic tumors. *Diagnostic Oncology*, 1993; 3: 45-48.
9. Westlin JE, **Janson ET**, Ahlström H, Öberg K, Nilsson S. Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide. *Acta Oncologica* 1993; Vol 32; No 7/8: 783-786.
10. **Janson ET**, Westlin JE, Eriksson B, Ahlström H, Nilsson S, Öberg K. [111In-DTPA-D-Phe]-octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment. *Eur J of Endocrinol* 1994; 131: 577-81.
11. Sorbe B, Andersson H, Schmidt M, Söderberg M, Högberg T, Wernstedt L, **Janson ET**, Ehrnström B, Kjaer M, Havsteen H, Overgaard M, Sandberg E, Flander M, Heikkinen M, Nikkanen V. Tropisetron (Navoban) in the prevention of chemotherapy induced nausea and vomiting - the nordic experience. *Supportive Care in Cancer* 1994; 2(6): 393-396.
12. Imam H, **Janson ET**, Gobl A, Alm G, Öberg K. Induction of MxA-mRNA in patients with neuroendocrine tumors after interferon treatment - lack of correlation to antitumor response. *Anti-Cancer Research* 1995; 15: 2191-2196.
13. Kälkner KM, **Janson ET**, Nilsson S, Carlsson S, Öberg K, Westlin JE. Somatostatin receptor scintigraphy in patients with carcinoid tumors: Comparison between radioligand uptake and tumor markers. *Cancer Research* 1995; 55: 5801-5804.
14. **Janson ET**, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E, Öberg K. Carcinoid tumors - analysis of prognostic factors and survival 301 patients from a referral center. *Annals of Oncology* 1997; 8: 685-690.
15. **Janson ET**, Gobl A, Kälkner KM, Öberg K. A comparison between the efficacy of somatostatin receptor scintigraphy and that of in situ hybridization for somatostatin receptor subtype 2 messenger RNA to predict therapeutic outcome in carcinoid patients. *Cancer Research* 1996; 56:2561-2565.
16. Eriksson B, **Janson ET**, Bax NDS, Mignon M, Morant R, Opolon P, Rougier P, Öberg KE. The use of new somatostatin analogs, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumors. *Digestion* 1996;57:S1:77-80.
17. Imam H, Eriksson B, Lukinius A, **Janson ET**, Lindgren PG, Wilander E, Öberg K. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs. *Acta Oncologica* 1997;36:607-614.
18. Zhou Y, Gobl A, Wang S, Jacobsen MB, **Janson ET**, Haines III Gk, Radosevich JA, Öberg K. Expression of p68 protein kinase and its prognostic significance during IFN-alpha therapy in patients with carcinoid tumours. *Eur J Cancer* 1998;34:2046-52.
19. **Janson ET**, Stridsberg M, Gobl A, Westlin JE, Öberg K. Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies. *Cancer Res.* 1998 Jun 1; 58(11): 2375-2378.

20. **Janson ET**, Kälkner KM, Eriksson B, Westlin JE, Öberg K. Somatostatin receptor scintigraphy during treatment with lanreotide in patients with neuroendocrine tumors. *Nuclear Medicine and Biology* 1999;26:877-882.
21. **Janson ET**, Westlin JE, Öhrvall U, Öberg K, Lukinius A. Nuclear localization of <sup>111</sup>In after intravenous injection of [<sup>111</sup>In-DTPA-D-Phe<sup>1</sup>]-octreotide to patients with neuroendocrine tumors. *J Nucl Med* 2000 Sep;41(9):1514-8.  
**ABSTRACTED** in the Year book of Nuclear Medicine 2001.
22. Skogseid B, Öberg K, Åkerström G, Eriksson B, Westlin JE, **Janson ET**, Eklöf H, Elvin A, Juhlin C, Rastad J. Limited Tumor Involvement Found at Multiple Endocrine Neoplasia Type I Pancreatic Exploration: Can It Be Predicted by Preoperative Tumor Localization? *World J Surg.* 1998 Jul; 22(7): 673-678.
23. **Janson ET**, Eriksson B, Öberg K, Skogseid B, Öhrvall U, Nilsson S, Westlin JE. Treatment with high dose Octreoscan in patients with neuroendocrine tumors - evaluation of therapeutic and toxic effects. *Acta Oncologica* 1999;38:373-377.
24. Lukinius A, Öhrvall U, Westlin JE, Öberg K and **Janson ET**. In vivo cellular distribution and endocytosis of the somatostatin receptor-ligand complex. *Acta Oncologica* 1999;38:383-387.
25. Georgii-Hemming P, Strömberg T, **Janson ET**, Stridsberg M, Wiklund HJ, Nilsson K. The somatostatin analogue octreotide inhibits growth of interleukin-6 (IL-6)-dependent and IL-6-independent human multiple myeloma cell lines. *Blood* 1999 Mar 1;93 (5): 1724-31.
26. Cunningham JL, Lopes Egidio JR, **Janson ET**, Eriksson B, Öberg K, Gobl A. Transmembrane protein tyrosine phosphatase IA-2 (ICA 512) is expressed in human midgut carcinoids but is not detectable in normal EC cells. *J Endocrinol* 2000 Mar;164(3):315-322
27. Portela-Gomes GM, Stridsberg M, Grimelius L, Öberg K, **Janson ET**. Expression of the five different somatostatin receptor subtypes in endocrine cells of the pancreas. *Applied Immunohistochemistry & Molecular Morphology* 2000;8(2):126-32.
28. Afargan M, **Janson ET**, Gelerman G, Rosenfeld R, Ziv O, Karpov O, Wolf A, Bracha M, Shohat D, Liapakis G, Gilon C, Hoffman A, Stephensky D, Öberg K. Novel long acting somatostatin analog with endocrine selectivity: Potent suppression of growth hormone but not of insulin. *Endocrinology*, 2001;142:477-486.
29. Fjällskog MLH, Granberg PDK, Welin LSV, Eriksson C, Öberg KE, **Janson ET**, Eriksson BK. Treatment with Cisplatin and Etoposide in Patients with Neuroendocrine Tumors. *Cancer* 2001;92:1101-1107.
30. Nilsson A., **Janson ET**, Eriksson B, Larsson A. Levels of angiogenic peptides in sera from patients with carcinoid tumours during alpha-interferon treatment. *Anticancer Research* 2001;21: 4087-4090.
31. Fjällskog ML, Sundin A, Westlin JE, Öberg K, **Janson ET**, Eriksson B. Treatment of malignant endocrine pancreatic tumors with a combination of a-interferon and somatostatin analogs. *Medical Oncology* 2002;19:35-42 .
32. Hellman P, Lundström T, Öhrvall U, Eriksson B, Skogseid B, Öberg K, **Tiensuu Janson E**, Åkerström G. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. *World J Surgery* 2002;26(8):991-997.
33. Fjällskog ML, Ludvigsen E, Stridsberg M, Öberg K, Eriksson B, **Janson ET**. Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. *Medical Oncology* 2003 Feb;20(1):59-68.
34. Fjällskog ML, Lejonklou MH, Öberg K, Eriksson B, **Janson ET**. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. *Clin Cancer Res.* 2003 Apr;9(4):1469-73.
35. Stridsberg M, Eriksson B, Öberg K, **Janson ET**. A comparison between three commercial kits for chromogranin A measurements *J Endocrinol* 2003 May;177(2):337-41
36. Granberg D, Sundin A, **Janson ET**, Öberg K, Skogseid B, Westlin JE. Octreoscan in patients with bronchial carcinoid tumors. *Clinical Endocrinology* 2003;59:793-799.
37. Stridsberg M, Eriksson B, Öberg K, **Janson ET**. A panel of eleven region-specific radioimmunoassays for measurements of human chromogranin A. *Regulatory Peptides* 2004; 117: 219-227.



38. Ludvigsen E, Olsson R, Stridsberg M, **Janson ET**, Sandler S. Expression and distribution of somatostatin receptor subtypes in the pancreatic islets of normal mice and rats. *J Histochemistry and Cytochemistry* 2004; 52: 391-400.
39. Welin S, **Janson ET**, Sundin A, Stridsberg M, Granberg D, Skogseid B, Öberg K, Eriksson B. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumors. *European Journal of Endocrinology* 2004; 151:107-112.
40. Tsolakis AV, Portela Gomes GM, Stridsberg M, Grimelius L, Sundin A, Eriksson B, Öberg K, **Janson ET**. Malignant gastric ghrelinoma with hyperghrelinemia. *J Clin Endocrinol Metabol* 2004; 89:3739-3744.
41. Ludvigsen E, Stridsberg M, Taylor JE, Culler MD, Öberg K, **Janson ET**. Subtype selective interactions of somatostatin and somatostatin analogues with sst<sub>1</sub>, sst<sub>2</sub> and sst<sub>5</sub> in BON-1 cells. *Medical Oncology* 2004;21(3):285-295.
42. Stridsberg M, Eriksson B, Öberg K, **Janson ET**. A panel of 13 region-specific radioimmunoassays for measurements of human chromogranin B. *Regulatory Peptides* 2005; 125: 193-199.
43. Ludvigsen E, Stridsberg M, **Janson ET**, Sandler S. Expression of somatostatin receptor subtypes 1 - 5 in pancreatic islets of normoglycaemic and diabetic NOD mice. *European J Endocrinology* 2005;153:445-454.
44. Welin S, Fjällskog ML, Saras J, Eriksson B, **Janson ET**. Expression of tyrosine kinase receptors in malignant midgut carcinoid tumors. *Neuroendocrinology* 2006;84:42-48.
45. Ludvigsen E, Stridsberg M, Taylor JE, Culler MD, Öberg K, **Janson ET**, Sandler S. Regulation of insulin and glucagon secretion by somatostatin receptor subtypes from rat pancreatic islets in vitro. *Regulatory Peptides* 2007;138:1-9.
46. Fjällskog ML, Hessman O, Eriksson B, **Janson ET**. Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas. *Acta Oncologica* 2007;46:741-746.
47. Stridsberg M, Eriksson B, Fellström B, Kristjansson G, **Janson ET**. Measurements of Chromogranin B can serve as a complement to chromogranin A. *Regulatory Peptides* 2007;139:80-83.
48. Granberg D, Eriksson LG, Welin S, Kindmark, H, **Janson ET**, Skogseid B, Öberg K, Eriksson B, Nyman R. Liver embolization with trisacryl gelatin microspheres (Embosphere) in patients with neuroendocrine tumors. *Acta Radiologica* 2007;2:180-185.
49. Cunningham J, Grimelius L, Sundin A, Agarwal S, **Janson ET**. Malignant Ileocaecal Serotonin-producing Carcinoid Tumours: The presence of a solid growth pattern and/or Ki67 index above 1% identifies patients with a poorer prognosis. *Acta Oncologica* 2007;46:747-756.
50. Kindmark H, Sundin A, Granberg D, Dunder K, Skogseid B, **Janson ET**, Welin S, Öberg K, Eriksson B. Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years. *Med Oncol.* 2007;24(3):330-7.
51. Ekeblad S, Sundin A, **Janson ET**, Welin S, Granberg D, Kindmark H, Dunder K, Kozlovacki G, Örelfors H, Sigurd M, Öberg K, Eriksson B, Skogseid B. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. *Clinical Cancer Research* 2007;13:2986-2991.
52. Saras J, Grönberg M, Stridsberg M, Öberg KE, **Janson ET**. Somatostatin induces rapid contraction of neuroendocrine cells. *FEBS Letters* 2007;581:1957-1962.
53. Portela-Gomes GM, Stridsberg M, Grimelius L, Rorstad O, **Janson ET**. Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas – predominance of receptor subtype 4. *Endocrine Pathology* 2007;18(2):79-85.
54. Larsson G and **Janson ET**. Anemia in patients with midgut carcinoid, treated with alpha interferon: effects by erythropoietin treatment on the perceived quality of life. *European Journal Of Cancer Care* 2008;17:200-204.
55. Tsolakis AV, Stridsberg M, Grimelius L, Portela-Gomes GM, Falkmer S, Waldum H, **Janson ET**. Ghrelin immunoreactive cells in gastric endocrine tumors and their relation to plasma ghrelin concentration. *Journal of Clinical Gastroenterology* 2008;42:381-388.
56. Fjällskog ML, **Janson ET**, Falkmer U, Vatn M, Öberg K, Eriksson B. Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors. *Neuroendocrinology* 2008;88:53-58.

57. Stridsberg M, Eriksson B, **Janson ET**. Measurements of secretogranins II, III, V and proconvertases 1/3 and 2 in plasma from patients with neuroendocrine tumours. *Regulatory Peptides* 2008;148:95-98.
58. Grönberg M, Tsolakis AV, Magnusson L, **Janson ET**, Saras J. Distribution of obestatin and ghrelin in human tissues: immunoreactive cells in the gastrointestinal tract, pancreas, and mammary glands. *J Histochem Cytochem* 2008;56:793-801.
59. Cunningham J, **Janson ET**, Agarwal S, Grimelius L, Stridsberg M. Tachykinins in endocrine tumors and the carcinoid syndrome. *Eur J Endocrinol* 2008;159:275-282.
60. Welin S, Stridsberg M, Cunningham J, Granberg D, Öberg K, Eriksson B, **Janson ET**. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. *Neuroendocrinology* 2009;89:302-307.
61. Tsolakis AV, Grimelius G, Stridsberg M, Falkmer S, Valdum H, Saras J, **Janson ET**. Obestatin/ghrelin cells in normal mucosa and endocrine tumours of the stomach. *Eur J Endocrinol* 2009;160:941-949.
62. Kindmark H, **Janson ET**, Gustavsson B, Eriksson C, Larsson G, Granberg D, Kozlocacki G, Skogseid B, Welin S, Öberg K, Eriksson B. Five patients with malignant endocrine tumors treated with imatinib mesylate (Glivec®). *Acta Oncologica* 2010;49:100-1.
63. Grönberg M, Amini RM, Stridsberg M, **Janson ET**, Saras J. Neuroendocrine markers are expressed in mammary glands. *Regulatory Peptides* 2010;160:68-74.
64. **Janson ET**, Sörbye H, Welin S, Federspiel B, Grönbäck H, Hellman P, Mathisen Ö, Mortensen J, Sundin A, Thiis-Evensen E, Välimäki M, Öberg K, Knigge U. Nordic guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. *Acta Oncologica* 2010;49:740-56.
65. Cunningham JL, Tsolakis A, Jacobson A, **Janson ET**. Connective tissue growth factor expression in endocrine tumours is associated with high stromal expression of alpha-smooth muscle actin. *Eur J Endocrinol* 2010;163:691-7.
66. Cunningham J, Diaz de Ståhl T, Sjöblom T, Westin G, Dumanski J, **Janson ET**. Common pathogenetic mechanism involving human chromosome 18 in familial and sporadic ileal carcinoid tumors. *Genes Chromosomes and Cancer* 2011;50:82-94
67. Georgantzi K, Tsolakis AV, Stridsberg M, Jakobsson Å, Christofferson R, **Janson ET**. Differentiated expression of somatostatin receptor subtypes in experimental models and clinical neuroblastoma. *Pediatric Blood and Cancer* 2011;56:584-589.
68. Walsh KM, Choi M, Öberg K, Kulke MH, Yao JC, Wu C, Jurkiewicz M, Hsu LI, Hooshmand SM, Hassan M, **Janson ET**, Cunningham J, Vosburgh E, Sackler RS, Lifton RP, Dewan AT, Hoh J. A pilot genome-wide association study shows rare copy-number variants enriched leucocytic genome of patients with ileal neuroendocrine tumors. *Endocrine Related Cancer* 2011;18:171-180.
69. Ludvigsen E, Stridsberg M, **Janson ET**, Sandler S. Altered expression of somatostatin receptors in pancreatic islets from NOD mice cultured at different glucose concentrations in vitro and in islets transplanted to diabetic NOD mice in vivo. *Experimental Diabetes Research* 2011;2011:623472
70. Grönberg M, Fjällskog ML, Jirstrom K, **Janson ET**. Expression of ghrelin is correlated to a favorable outcome in invasive breast cancer. *Acta Oncologica* 2012;51:386-93.
71. Norlén O, Ståhlberg P, Öberg K, Eriksson J, Hedberg J, Hessman O, **Tiensuu Janson E**, Hellman P, Åkerström G. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. *World J Surg.* 2012;36:1419-31.
72. Pazaitou-Panayiotou K, **Tiensuu Janson E**, Koletsa T, Kotoula V, Stridsberg M, Karkavelas G, Karayannopoulou G. Somatostatin receptor expression in non-medullary thyroid carcinomas. *Hormones* 2012;11:290-296.
73. Sorbye H, Welin S, Langer S, Westermarck L, Holt N, Osterlund P, Dueland S, Hofslie E, Guren M, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Holst I, Federspiel B, Assmus J, **Janson ET\***, Knigge U\*. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. *Annals of Oncology* 2013;1:152-60. \*shared last authorship.
74. Grönberg M, Tsolakis A, Holmbäck U, Stridsberg M, Grimelius L, **Janson ET**. Ghrelin and obestatin in human neuroendocrine tumors: Expression and effect on obestatin levels after meal intake. *Neuroendocrinology* 2013;97:291-9.

75. Edfeldt K, Ahmad T, Åkerström G, **Janson ET**, Hellman P, Stålberg P, Björklund P, Westin G. TCEB3C a putative tumor suppressor gene of small intestine neuroendocrine tumors. *Endocrine Related Cancer* 2014;21:275-284.
76. Forsberg LA, Rasi C, Malmqvist N, Davies H, Pasupulati S, Pakalapati G, Sandgren J, Diaz de Ståhl T, Zaghlool A, Giedraitis V, Lannfelt L, Score J, Cross NCP, Absher D, **Janson ET**, Lindgren CM, Morris AP, Ingelsson E, Lind L, Dumanski JP. Loss of human chromosome Y is associated with shorter survival and higher risk of cancer. *Nature Genetics* 2014; 46:624-8.
77. **Janson ET**, Sorbye H, Welin S, Federspiel B, GronbackH, Hellman P, Laderkarl M, Langer SW, Mortensen J, Schalin-Jäntti C, Sundin A, Sundlöv A, Thiis-Evensen E, Knigge U. Nordic Guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. *Acta Oncologica* 2014;53:1284-97.
78. **Janson ET**. Treatment with somatostatin analogues may delay progression of neuroendocrine tumours. *Acta Onologica* 2014;53:1283.
79. Dumanski JP, Rasi C, Lönn M, Davies H, Ingelsson M, Giedraitis V, Lannfelt L, Magnusson P, Lindgren CM, Morris AP, Cesarini D, Johannesson M, **Tiensuu Janson E**, Lind L, Pedersen NL, Ingelsson E, Forsberg LA. Mutagenesis. Smoking is associated with mosaic loss of chromosome Y. *Science* 2015;347:81-3
80. Ludvigsen E, Carlsson C, **Tiensuu Janson E**, Sandler S, Stridsberg M. Somatostatin receptor 1-5; expression profiles during rat development. *Uppsala Journal of Medical Sciences* 2015;120:157-68.
81. Forsberg LA, Pekar G, Rasi C, Dvaies H, Piotrowski A, Absher D. Ambicka A, Halaszka K, Przewoznik M, Razzaghian HR, Pakalapati S, Pasupulati S, Hacker J, Prakash KR, Lau J, Penagos-Tafurt N, Olofsson H, Hallberg G, Skotnicki P, Mitus J, Skokowski J, Jankowski M, Srutek E, Zegarski W, **Janson ET**, Rys J, Tot T, Dumanski JP. Signatures of post-zygotic structural genetic aberrations in histologically normal breast cells predisposing to development of sporadic breast cancer. *Genome research* 2015;25:1521-35.
82. Tsolakis AV, Grimelius L, Granérus G, Stridsberg M, Falkmer SE, **Janson ET**. Histidine decarboxylase and urinary methylimidazoleacetic acid in gastric neuroendocrine cells and tumours. *World Journal of Gastroenterology* 2015;21:13240-13249.
83. Haugvik SP, **Janson ET**, Österlund P, Langer SW, Falk RS, Labori KJ, Vestermark LW, Groenbaek H, Gladhaug IP, Sorbye H. Surgical treatment as a principle for patients with high-grade pancreatic neuroendocrine carcinoma: a Nordic multicenter comparative study. *Annals of Surgical Oncology* 2016;23:1721-8.
84. Söderquist F, **Janson ET**, Rasmusson AJ, Ali A, Stridsberg M, Cunningham JL. Melatonin immunoreactivity in malignant small intestinal neuroendocrine tumours. *PLoS One* 2016 Oct 13;11(10):e0164354. doi: 10.1371.
85. Edfeldt K, Daskalakis K, Bäcklin C, Norlén O, **Tiensuu Janson E**, Westlin G, Hellman P, Stålberg P. DcR3, TTF3 and Midkine are novel serum biomarkers in small intestinal neuroendocrine tumors. *Neuroendocrinology* 2017;105(2):170-181.
86. Kaltsas G, Caplin M, Davies F, Ferone D, Garcia-Carbonero R, Grozinsky-Glasber S, Hörsch D, **Tiensuu Janson E**, Kiamanesh R, Kos-Kudla B, Pavel M, Rinke A, Falconi M, de Herder WW. ENETS consensus guidelines for the standard of care in neuroendocrine tumors: pre- and perioperative therapy in patients with neuroendocrine tumors. *Neuroendocrinology* 2017;105(3):245-254.
87. Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, Borbath I, Cwikla J, Toumpanakis C, Kaltsas G, Davies P, Hörsch D, **Tiensuu Janson E**, Ramage J. ENETS consensus guidelines for the standards of care in neuroendocrine tumours; peptide receptor radionuclide therapy with radiolabeled somatostatin analogues. *Neuroendocrinology* 2017;105(3):295-309.
88. Grönberg M, Ahlin C, Naeser Y, **Janson ET**, Holmberg L, Fjällskog ML. Ghrelin is a prognostic marker and a potential therapeutic target in breast cancer. *PLoS One* 2017;12(4):e0176059.
89. Galleberg R, Knigge U, **Tiensuu Janson E**, Vestermark LW, Haugvik SP, Ladekarl M, Langer SW, Gronbaek H, Österlund P, Hjortland GO, Assmus J, Tang L, Perenn A, Sorbye H. Results after surgical resection of liver metsastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. *Eur J Surg Oncol* 2017;43(9):1682-1689.

90. Dumanski JP, Rasi C, Björklund P, Davies H, Ali AS, Grönberg M, Welin S, Sorbye H, Groenbaek H, Cunningham JL, Forsberg L, Lind L, Ingelsson E, Stålberg P, Hellman P, **Tiensuu Janson E**. A MUTYH germline mutation is associated with small intestinal neuroendocrine tumors. *Endocr Relat Cancer* 2017;24(8):427-443.
91. Ali AS, Grönberg M, Federspiel B, Soazec JY, Hjortland GO, Groenbaek H, Ladekarl M, Langer SW, Welin S, Vestermark LW, Arola J, Österlund P, Knigge U, Sorbye H, Grimelius L, **Janson ET**. Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma. *PLoS One* 2017;12(11):e0187667.
92. Daskalakis K, Karakatsanis A, Hessman O, Stuart HC, Welin S, **Tiensuu Janson E**, Öberg K, Hellman P, Norlén O, Stålberg P. Association of a prophylactic surgical approach to stage IV small intestinal neuroendocrine tumors with survival. *JAMA Oncol* 2018;4(2):183-189.
93. Ali AS, Grönberg M, Langer SW, Ladekarl M, Hjortland GO, Vestermark LW, Österlund P, Welin S, Groenbaek H, Knigge U, Sorbye H, Janson ET. Intravenous versus oral etoposide: Efficacy and correlation to clinical outcome in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). *Medical Oncology* 2018;35:47
94. Georgantzi K, Sköldenberg EG, Stridsberg M, Kogner P, Jakobson Å, **Janson ET**, Christofferson RHB. Chromogranin A and neuron-specific enolase in neuroblastoma: correlation to stage and prognostic factors. *Pediatric Hematology and Oncology* 2018;35(2):156-165.
95. Grönberg M, Nilsson C, Johansson I, Hedenfalk I, Blomqvist C, Valachis A, Holmberg L, **Tiensuu Janson E**, Fjällskog ML. Ghrelin expression is associated with a favorable outcome in male breast cancer. *Scientific Reports* 2018 Sep 11;8(1):13586. doi: 10.1038/s41598-018-31783-x.
96. Toumpanakis C, Fazio N, **Tiensuu Janson E**, Hörsch D, Pascher A, Reed N, O'Toole D, Nieveen van Dijkum E, Partelli S, Rinke A, Kos-Kudla B, Costa F, Pape U, Grozinsky-Glasberg S, Scoazec JY. Unmet needs in appendiceal neuroendocrine neoplasms. *Neuroendocrinology* 2019;108 (1):37-44. doi: 10.1159/000493894
97. Georgantzi K, Sköldenberg E, **Janson ET**, Jakobson Å, Christofferson R. Diagnostic Ultrasound-guided cutting needle biopsies in neuroblastoma: a safe and efficient procedure. *Journal of Pediatric Surgery* 2019 Jun;54(6):1253-1256.
98. Georgantzi K, Tsolakis AV, Jakobson Å, Christofferson R, **Janson ET**, Grimelius L. Synaptic vesicle protein 2 and vesicular monoamine transporter 1 and 2 are expressed in neuroblastoma. *Endocrine Pathology* 2019;30(3):173-179
99. Dam G, Gronbaek H, Sorbye H, Thiis-Evensen E, Paulsen B, Sundin A, Jensen C, Ebbesen D, Knigge U, **Tiensuu Janson E**. Prospective study of chromogranin A as a predictor of progression in patients with pancreatic, small intestinal and unknown primary neuroendocrine tumors. *Neuroendocrinology* 2020;110(3-4):217-224.
100. Lase I, Strele I, Grönberg M, Kozlovacki G, Welin S, **Janson ET**. Multiple hormone secretion may indicate worse prognosis in patients with ectopic Cushing's syndrome. *Hormones* 2020;19(3):351-360.
101. Ali AS, Perren A, Lindskog C, Welin S, Sorbye H, Grönberg M, **Janson ET**. Serum biomarkers in Pancreatic G3 Neuroendocrine Neoplasms. *Scientific Reports* June 30;10(1):10639
102. Elvebakken H, Perren A, Scoazec JY, Tang L, Federspiel B, Klimstra D, Vestermark L, Ali AS, Zlobec I, Myklebust TÅ, Hjortland GO, Langer SW, Gronbaek H, Knigge U, **Tiensuu Janson E\***, Sorbye H\*. A Consensus developed morphological re-evaluation of 196 high-grade gastroenteropancreatic neuroendocrine neoplasms and its clinical correlations. *Neuroendocrinology* 2021;111(9):883-894 \*shared last authorship
103. Papantoniou D, Grönberg M, Linderholm K, Welin S, Ziolkowska B, Nordvall D, **Janson ET**. Hormonal levels as prognostic markers in small intestinal neuroendocrine tumours grade 2. *Endocrine* 2021;72(3):893-904.
104. Ali AS, Grönberg M, Federspiel B, Hjortland GO, Gronbaek H, Ladekarl M, Langer SW, Welin S, Vestermark LW, Arola J, Österlund P, Knigge U, Sorbye H, Grimelius L, Micke P, **Tiensuu Janson E**. PDL1 expression in Gastroenteropancreatic Neuroendocrine Neoplasms Grade 3. *PLoS One* 2020 Dec. 14;15(12):e0243900
105. Pommergaard, HC, Nielsen K, Sorbye H, Federspiel B, Tabaksblat E, Vestermark L, **Janson ET**, Hansen CP, Ladekarl M, Garresori H, Hjortland G, Sundlöf A, Galleberg R, Knigge P, Kjaer

- A, Langer SW, Knigge U. Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non neuroendocrine neoplasms. *J Neuroendocrinology* 2021;33(5)e12967.
106. **Janson ET**, Knigge U, Dam G, Federspiel B, Gronbaek H, Stålberg P, Lander SW, Kjaer A, Arola J, Schalin-Jääntti C, Sundin A, Welin S, Thiis-Evensen E, Sorbye H. Nordic Guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. *Acta Oncologica* 2021;60:931-941.
107. Lase I, Grönberg M, Norlén, O, Stålberg P, Welin S, **Janson ET**. Adrenalectomy in Ectopic Cushing's syndrome: a retrospective cohort study from a tertiary care centre. *J Neuroendocrinology* 2021;33:e13030
108. Wedin M, Tsoi M, Wallin G, **Janson ET**, Koumariou A, Kaltsas G, Daskalakis K. Heterogeneity of small intestinal neuroendocrine tumors metastasis: biological patterns of a series with Virchow's node involvement. *Cancers* 2022;14:913.

### Study Group Author

1. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M, Leboulloux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler M, de la Fouchardière C, Schlumberger M, Mantero F, Weismann D, Beuschlein F, Gelderblom H, Wilmink H, Sender M, Edgerly M, Kenn W, Fojo T, Müller HH, Skogseid B; FIRM-ACT Study Group. Combination chemotherapy in advanced adrenocortical carcinoma. *N Engl J Med* 2012;366:2189-97.
2. Perren A, Couvelard A, Scoazec JY, Costa F, Borbath I, Delle Fave G, Gorbounova V, Gross D, Grossma A, Jense RT, Kulke M, Oeberg K, Rindi G, Sorbye H, Welin S; Antibes Consensus Conference participants. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification. *Neuroendocrinology*. 2017;105(3):196-200. doi: 10.1159/000457956. PMID:28190015
3. Knigge U, Capdevila J, Bartsch DK, Baudin E, Falkerby J, Kianmanesh R, Kos-Kudla B, Niederle B, Nieveen van Dijkum E, O'Toole D, Pascher A, Reed N, Sundin A, Vullierme MP; Antibes Consensus Conference Participants; Antibes Consensus Conference participants. ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation. *Neuroendocrinology*. 2017;105(3):310-319. doi: 10.1159/000458155. Epub PMID:28222443
4. Partelli S, Bartsch DK, Capdevila J, Chen J, Knigge U, Niederle B, Nieveen van Dijkum EJM, Pape UF, Pascher A, Ramage J, Reed N, Ruzsniowski P, Scoazec JY, Toumpanakis C, Kianmanesh R, Falconi M; Antibes Consensus Conference participants. ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours. *Neuroendocrinology*. 2017;105(3):255-265. doi: 10.1159/000464292. PMID:28237989
5. Pavel M, Valle JW, Eriksson B, Rinke A, Caplin M, Chen J, Costa F, Falkerby J, Fazio N, Gorbounova V, de Herder W, Kulke M, Lombard-Bohas C, O'Connor J, Sorbye H, Garcia-Carbonero R; Antibes Consensus Conference Participants; Antibes Consensus Conference participants. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. *Neuroendocrinology*. 2017;105(3):266-280. doi: 10.1159/000471880. PMID:28351033
6. Sundin A, Arnold R, Baudin E, Cwikla JB, Eriksson B, Fanti S, Fazio N, Giammarile F, Hicks RJ, Kjaer A, Krenning E, Kwekkeboom D, Lombard-Bohas C, O'Connor JM, O'Toole D, Rockall A, Wiedenmann B, Valle JW, Vullierme MP; Antibes Consensus Conference participants. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging. *Neuroendocrinology*. 2017;105(3):212-244. doi: 10.1159/000471879. PMID:28355596
7. Garcia-Carbonero R, Rinke A, Valle JW, Fazio N, Caplin M, Gorbounova V, O'Connor J, Eriksson B, Sorbye H, Kulke M, Chen J, Falkerby J, Costa F, de Herder W, Lombard-Bohas C, Pavel M; Antibes Consensus Conference participants. ENETS Consensus Guidelines for the

- Standards of Care in Neuroendocrine Neoplasms. Systemic Therapy 2: Chemotherapy. *Neuroendocrinology*. 2017;105(3):281-294. doi: 10.1159/000473892. PMID:28380493
8. Oberg K, Couvelard A, Delle Fave G, Gross D, Grossman A, Jensen RT, Pape UF, Perren A, Rindi G, Ruzsniwski P, Scoazec JY, Welin S, Wiedenmann B, Ferone D; Antibes Consensus Conference participants. ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Biochemical Markers. *Neuroendocrinology*. 2017;105(3):201-211. doi: 10.1159/000472254. PMID:28391265
  9. Sorbye H, Baudin E, Borbath I, Caplin M, Chen J, Cwikla JB, Frilling A, Grossman A, Kaltsas G, Scarpa A, Welin S, Garcia-Carbonero R; ENETS 2016 Munich Advisory Board Participants. Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3). *Neuroendocrinology*. 2019;108(1):54-62. doi: 10.1159/000493318. PMID:30153658
  10. Capdevila J, Bodei L, Davies P, Gorbounova V, Jensen RT, Knigge UP, Krejs GJ, Krenning E, O'Connor JM, Peeters M, Rindi G, Salazar R, Vullierme MP, Pavel ME; ENETS 2016 Munich Advisory Board Participants; ENETS 2016 Munich Advisory Board Participants. Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms. *Neuroendocrinology*. 2019;108(1):18-25. doi: 10.1159/000493319. Epub 2018 Aug 28. PMID:30153686
  11. Ramage JK, Valle JW, Nieveen van Dijkum EJM, Sundin A, Pascher A, Couvelard A, Kloeppel G; the ENETS 2016 Munich Advisory Board Participants; ENETS 2016 Munich Advisory Board Participants. Colorectal Neuroendocrine Neoplasms: Areas of Unmet Need. *Neuroendocrinology*. 2019;108(1):45-53. doi: 10.1159/000493767. PMID:30219817
  12. Baudin E, Hayes AR, Scoazec JY, Filosso PL, Lim E, Kaltsas G, Frilling A, Chen J, Kos-Kudła B, Gorbounova V, Wiedenmann B, Nieveen van Dijkum E, Cwikla JB, Falkerby J, Valle JW, Kulke MH, Caplin ME; ENETS 2016 Munich Advisory Board Participants; ENETS 2016 Munich Advisory Board Participants. Unmet Medical Needs in Pulmonary Neuroendocrine (Carcinoid) Neoplasms. *Neuroendocrinology*. 2019;108(1):7-17. doi: 10.1159/000493980. PMID:30248673
  13. Jensen RT, Bodei L, Capdevila J, Couvelard A, Falconi M, Glasberg S, Kloppel G, Lamberts S, Peeters M, Rindi G, Rinke A, Rothmund M, Sundin A, Welin S, Fazio N; The ENETS 2016 Munich Advisory Board Participants; ENETS 2016 Munich Advisory Board Participants. Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms. *Neuroendocrinology*. 2019;108(1):26-36. doi: 10.1159/000494258. PMID:30282083
  14. de Herder WW, Capdevila J; ENETS 2016 Munich Advisory Board Participants. Unmet Needs in the Field of Neuroendocrine Neoplasms of the Gastrointestinal Tract, Pancreas, and Respiratory System: Reports by the ENETS Group. *Neuroendocrinology*. 2019;108(1):5-6. doi: 10.1159/000495036. PMID:30517944

### Reviews and chapters in textbooks

1. Eriksson B, **Janson ET**, Skogseid B Öberg K. Ny medicinsk behandling av neuroendokrina gastrointestinala tumörer. *Läkartidningen* 1990; 35: 2668-72.
2. Westlin JE, **Janson ET**, Ahlström H, Öhrvall U, Arnberg H, Nilsson S, Åkerström G, Öberg K. Ny diagnostisk metod. Somatostatinreceptor-scintigrafi av neuroendokrina tumörer. *Läkartidningen* 1992; 50: 4377-4379.
3. Öberg K, Eriksson B, **Janson ET**. Interferons alone or in combination with chemotherapy or other biologicals. *Digestion* 1994; 55 Suppl 3: 64-69.
4. Öberg K, Eriksson B, **Janson ET**. The clinical use of interferons in the management of neuroendocrine gastroenteropancreatic tumors. *Molecular and Cell Biological Aspects of Gastroenteropancreatic Neuroendocrine Tumor Disease*. Eds Wiedenmann B, Kvols LK, Arnold R, Reicken EO. *Annals of the New York Academy of Sciences* 1994; 733: 471-478.
5. **Janson ET**, Öberg K. Carcinoid tumours. In: *Clinical Gastroenterology*, Eds Bloom SR, O'Shea, Bailliere's Tindall London 1996; 10:4, 589-601.
6. **Janson ET**, Öberg K. Somatostatin receptor ligands and their use in the treatment of endocrine disorders. *Curr Pharm Des*. 1999 Sep 1;5(9):693-705.
7. Öberg K, **Janson ET**, Eriksson B. Tumour markers in neuroendocrine tumours. *Ital J Gastroenterol Hepatol* 1999;31(Suppl.2):S160-2.

8. **Janson ET** and Öberg K. Malignant Neuroendocrine Tumors. Cancer Chemotherapy and Biological Response Modifiers, Annual 20 (Elsevier Science B.V.); Eds Giaccone G, Schilsky R and Sondel P. 2002;463-470.
9. **Janson ET** and Öberg K. Neuroendocrine Tumors –Somatostatin Receptor Expression and Somatostatin Analog Treatment. Cancer Chemotherapy and Biological Response Modifiers, Annual 21 (Elsevier Science B.V.); Eds Giaccone G, Schilsky R and Sondel P 2003; 535-546.
10. **Janson ET**. Carcinoid Tumors. Oncology Review series 2003;3:2-6.53.
11. Fjällskog ML and Janson ET. Tratamento dos tumores endócrinos do pâncreas (Treatment of endocrine pancreatic tumors) Cancer Hoje 2004, vol 2, no 5; 17-25.
12. Stridsberg M, **Janson ET**, Portela-Gomes GM. Cellular localisation of chromogranins and processed products in the diffuse neuroendocrine system and related tumours. In Current Medicinal Chemistry- Immunology, Endocrine & Metabolic Agents. Hot topic issue 2004."Chromogranin A and its derived peptides as potential regulators of immune, endocrine and metabolic systems – In search of its physiological role" Guest Editors: Karen B. Helle and Guldborg Serck-Hanssen. Vol 4;149-160.
13. Fjällskog ML and **Janson ET**. Treatment of Endocrine pancreatic tumors. Acta Oncologica 2005;44:328-338.
14. **Janson ET**. Carcinoider, gastrointestinala. Internetmedicin, 2004, reviderad 2007.
15. **Janson ET** and Öberg K. The carcinoid syndrome. In Gastroenterology and Hepatology: the Modern Clinician´s Guide. (Elsevier Science) Eds Weinstein WM, Hawkey CJ and Bosch J, 2005; chapter 110: pp 823-830.
16. **Janson ET** and Öberg K. Carcinoid Tumors. In Oncology-Hematology Source Book: Evidence-Based Practice. (McGraw Hill) Eds. Boyiadzis, Lebowitz Fojo, 2006; chapter 7: 72-79.
17. **Janson ET**. Somatostatin analogs in the treatment of neuroendocrine gastroenteropancreatic and intrathoracic tumors. J Endocrinological Investigation 2005; 28 (suppl to no 11):137-140.
18. Granberg D, Eriksson B, **Janson ET**, Öberg K, Skogseid B. Lungcarcinoider – inte så benigna som man trott. Läkartidningen 2006;34:2382-2384.
19. **Janson ET**. Treatment of neuroendocrine tumors with somatostatin analogs. Pituitary 2006;9:249-256.
20. Tsolakis AV, **Janson ET**. Endocrine Pancreatic Tumors: Diagnosis and treatment. Expert Review of Endocrinology & Metabolism 2008;3:187-205.
21. Cunningham J, **Janson ET**. The biological hallmarks of ileal carcinoids. Eur J Clin Invest 2011;41:1353-1360.

## Manuscripts

1. Bruhn-Olszewska B, Hanna Davies H, Sarkisyan I D, Juhas U, Rychlicka-Buniowska E, Wójcik M, Horbacz M, Jąkalski M, Olszewski P, Westholm JO, Smialowska A, Wierzba K, Torinsson Naluai Å, Jern J, Andersson LM, Järhult JD, Filipowicz N, **Janson ET**, Rubertsson S, Lipcsey M, Gisslén M, Hultström M, Robert Frithiof R, Dumanski JP. Loss of Y in leukocytes as a risk factor for critical COVID-19 in men. (submitted)
2. Papanтониou D, Grönberg M, Thiis-Evensen E, Sorbye H, Landerholm K, Welin S, **Janson ET**. Treatment efficacy in metastatic small intestinal neuroendocrine tumours grade 2. (manuscript)